Does the media refer more to DNA or TWST?

In the previous week, Twist Bioscience had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 15 mentions for Twist Bioscience and 10 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.65 beat Ginkgo Bioworks' score of 0.36 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 6 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ILMN or TWST?

Illumina has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Illumina $4.34B 8.33 $850M $5.36 44.71 Twist Bioscience $376.57M 27.81 -$77.67M -$2.22 N/A

Does the media favor ILMN or TWST?

In the previous week, Twist Bioscience had 3 more articles in the media than Illumina. MarketBeat recorded 15 mentions for Twist Bioscience and 12 mentions for Illumina. Illumina's average media sentiment score of 0.97 beat Twist Bioscience's score of 0.65 indicating that Illumina is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 7 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 6 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TWST or MTD?

In the previous week, Twist Bioscience had 7 more articles in the media than Mettler-Toledo International. MarketBeat recorded 15 mentions for Twist Bioscience and 8 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.01 beat Twist Bioscience's score of 0.65 indicating that Mettler-Toledo International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 6 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mettler-Toledo International 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, MEDP or TWST?

Medpace has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.75 $451.12M $17.06 35.89 Twist Bioscience $376.57M 27.81 -$77.67M -$2.22 N/A

Is MEDP or TWST more profitable?

Medpace has a net margin of 17.67% compared to Twist Bioscience's net margin of -31.66%. Medpace's return on equity of 110.15% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Twist Bioscience -31.66% -28.64% -19.94%

Does the media prefer MEDP or TWST?

In the previous week, Twist Bioscience had 3 more articles in the media than Medpace. MarketBeat recorded 15 mentions for Twist Bioscience and 12 mentions for Medpace. Medpace's average media sentiment score of 0.86 beat Twist Bioscience's score of 0.65 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 6 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TWST or RVTY?

Revvity has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 27.81 -$77.67M -$2.22 N/A Revvity $2.86B 5.61 $241.20M $2.10 68.38

Does the media refer more to TWST or RVTY?

In the previous week, Twist Bioscience had 4 more articles in the media than Revvity. MarketBeat recorded 15 mentions for Twist Bioscience and 11 mentions for Revvity. Twist Bioscience's average media sentiment score of 0.65 beat Revvity's score of 0.55 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 6 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Twist Bioscience (TWST) Competitors

$166.99 +11.43 (+7.35%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$167.60 +0.61 (+0.37%)

As of 09/18/2026 07:53 PM Eastern

Compare

TWST vs. DNA, ILMN, MTD, MEDP, and RVTY

Should you buy Twist Bioscience stock or one of its competitors? Twist Bioscience's main competitors and comparable companies include Ginkgo Bioworks (DNA), Illumina (ILMN), Mettler-Toledo International (MTD), Medpace (MEDP), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Twist Bioscience compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Twist Bioscience had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 15 mentions for Twist Bioscience and 10 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.65 beat Ginkgo Bioworks' score of 0.36 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	6 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ginkgo Bioworks has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.12	-$312.76M	-$5.01	N/A
Twist Bioscience	$376.57M	27.81	-$77.67M	-$2.22	N/A

Twist Bioscience has a net margin of -31.66% compared to Ginkgo Bioworks' net margin of -259.96%. Twist Bioscience's return on equity of -28.64% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Ginkgo Bioworks currently has a consensus price target of $6.33, suggesting a potential downside of 19.62%. Twist Bioscience has a consensus price target of $103.00, suggesting a potential downside of 38.32%. Given Ginkgo Bioworks' higher probable upside, equities research analysts clearly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Illumina?

Illumina (NASDAQ:ILMN) and Twist Bioscience (NASDAQ:TWST) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Illumina presently has a consensus target price of $199.13, suggesting a potential downside of 16.90%. Twist Bioscience has a consensus target price of $103.00, suggesting a potential downside of 38.32%. Given Illumina's higher probable upside, analysts plainly believe Illumina is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Illumina has a net margin of 18.36% compared to Twist Bioscience's net margin of -31.66%. Illumina's return on equity of 29.84% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Illumina has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market.

In the previous week, Twist Bioscience had 3 more articles in the media than Illumina. MarketBeat recorded 15 mentions for Twist Bioscience and 12 mentions for Illumina. Illumina's average media sentiment score of 0.97 beat Twist Bioscience's score of 0.65 indicating that Illumina is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	7 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	6 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.4% of Illumina shares are owned by institutional investors. 2.9% of Illumina shares are owned by insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Illumina has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	8.33	$850M	$5.36	44.71
Twist Bioscience	$376.57M	27.81	-$77.67M	-$2.22	N/A

Summary

Illumina beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Mettler-Toledo International?

Twist Bioscience (NASDAQ:TWST) and Mettler-Toledo International (NYSE:MTD) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Mettler-Toledo International has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	27.81	-$77.67M	-$2.22	N/A
Mettler-Toledo International	$4.03B	6.93	$869.19M	$44.43	31.36

Mettler-Toledo International has a net margin of 21.91% compared to Twist Bioscience's net margin of -31.66%. Twist Bioscience's return on equity of -28.64% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Mettler-Toledo International	21.91%	-1,212.14%	25.11%

In the previous week, Twist Bioscience had 7 more articles in the media than Mettler-Toledo International. MarketBeat recorded 15 mentions for Twist Bioscience and 8 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.01 beat Twist Bioscience's score of 0.65 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	6 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mettler-Toledo International	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.1% of Mettler-Toledo International shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Twist Bioscience has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Twist Bioscience presently has a consensus target price of $103.00, suggesting a potential downside of 38.32%. Mettler-Toledo International has a consensus target price of $1,446.36, suggesting a potential upside of 3.82%. Given Mettler-Toledo International's higher probable upside, analysts clearly believe Mettler-Toledo International is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.31

Summary

Mettler-Toledo International beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Medpace?

Medpace (NASDAQ:MEDP) and Twist Bioscience (NASDAQ:TWST) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

78.0% of Medpace shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medpace has a net margin of 17.67% compared to Twist Bioscience's net margin of -31.66%. Medpace's return on equity of 110.15% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Twist Bioscience	-31.66%	-28.64%	-19.94%

In the previous week, Twist Bioscience had 3 more articles in the media than Medpace. MarketBeat recorded 15 mentions for Twist Bioscience and 12 mentions for Medpace. Medpace's average media sentiment score of 0.86 beat Twist Bioscience's score of 0.65 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	6 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.75	$451.12M	$17.06	35.89
Twist Bioscience	$376.57M	27.81	-$77.67M	-$2.22	N/A

Medpace currently has a consensus price target of $595.20, indicating a potential downside of 2.80%. Twist Bioscience has a consensus price target of $103.00, indicating a potential downside of 38.32%. Given Medpace's higher probable upside, analysts clearly believe Medpace is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market.

Summary

Medpace beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Revvity?

Twist Bioscience (NASDAQ:TWST) and Revvity (NYSE:RVTY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

86.7% of Revvity shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by company insiders. Comparatively, 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Revvity has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	27.81	-$77.67M	-$2.22	N/A
Revvity	$2.86B	5.61	$241.20M	$2.10	68.38

Twist Bioscience presently has a consensus price target of $103.00, indicating a potential downside of 38.32%. Revvity has a consensus price target of $116.57, indicating a potential downside of 18.82%. Given Revvity's higher probable upside, analysts clearly believe Revvity is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Twist Bioscience has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, Revvity has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

In the previous week, Twist Bioscience had 4 more articles in the media than Revvity. MarketBeat recorded 15 mentions for Twist Bioscience and 11 mentions for Revvity. Twist Bioscience's average media sentiment score of 0.65 beat Revvity's score of 0.55 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	6 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has a net margin of 8.16% compared to Twist Bioscience's net margin of -31.66%. Revvity's return on equity of 8.34% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Revvity	8.16%	8.34%	5.01%

Summary

Revvity beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

Get Twist Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TWST vs. The Competition

Export

Metric	Twist Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.47B	$10.40B	$7.24B	$13.19B
Dividend Yield	N/A	1.46%	2.57%	12.81%
P/E Ratio	-75.22	56.57	214.59	20.89
Price / Sales	27.81	108.53	646.01	89.45
Price / Cash	N/A	27.47	76.25	51.42
Price / Book	21.30	5.70	10.46	6.33
Net Income	-$77.67M	$56.67B	$3.49B	$358.33M
7 Day Performance	31.26%	4.59%	0.59%	1.12%
1 Month Performance	17.28%	1.52%	-2.01%	-2.67%
1 Year Performance	498.75%	28.13%	18.09%	6.01%

Twist Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TWST Twist Bioscience	1.849 of 5 stars	$166.99 +7.3%	$103.00 -38.3%	+497.5%	$10.47B	$376.57M	N/A	979	Analyst Forecast
DNA Ginkgo Bioworks	1.293 of 5 stars	$7.85 +11.2%	$6.33 -19.3%	-31.0%	$475.42M	$170.15M	N/A	485	News Coverage High Trading Volume
ILMN Illumina	2.1915 of 5 stars	$245.18 +7.1%	$199.13 -18.8%	+132.6%	$34.57B	$4.49B	45.74	8,650
MTD Mettler-Toledo International	4.0412 of 5 stars	$1,411.18 +2.4%	$1,446.36 +2.5%	+8.1%	$27.62B	$4.03B	31.76	18,100	Positive News
MEDP Medpace	2.6278 of 5 stars	$615.18 -0.2%	$595.20 -3.2%	+22.0%	$17.21B	$2.53B	36.06	6,200	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TWST) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Competitors

TWST vs. DNA, ILMN, MTD, MEDP, and RVTY

How does Twist Bioscience compare to Ginkgo Bioworks?

Summary

How does Twist Bioscience compare to Illumina?

Summary

How does Twist Bioscience compare to Mettler-Toledo International?

Summary

How does Twist Bioscience compare to Medpace?

Summary

How does Twist Bioscience compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Competitors

TWST vs. DNA, ILMN, MTD, MEDP, and RVTY

How does Twist Bioscience compare to Ginkgo Bioworks?

Does the media refer more to DNA or TWST?

Which has more volatility & risk, DNA or TWST?

Do institutionals and insiders have more ownership in DNA or TWST?

Which has better valuation & earnings, DNA or TWST?

Is DNA or TWST more profitable?

Do analysts recommend DNA or TWST?

Summary

How does Twist Bioscience compare to Illumina?

Do analysts recommend ILMN or TWST?

Is ILMN or TWST more profitable?

Which has more volatility and risk, ILMN or TWST?

Does the media favor ILMN or TWST?

Do insiders & institutionals hold more shares of ILMN or TWST?

Which has stronger earnings & valuation, ILMN or TWST?

Summary

How does Twist Bioscience compare to Mettler-Toledo International?

Which has stronger earnings & valuation, TWST or MTD?

Is TWST or MTD more profitable?

Does the media prefer TWST or MTD?

Do insiders and institutionals have more ownership in TWST or MTD?

Which has more volatility & risk, TWST or MTD?

Do analysts prefer TWST or MTD?

Summary

How does Twist Bioscience compare to Medpace?

Do institutionals and insiders believe in MEDP or TWST?

Is MEDP or TWST more profitable?

Does the media prefer MEDP or TWST?

Which has better earnings & valuation, MEDP or TWST?

Do analysts prefer MEDP or TWST?

Which has more volatility and risk, MEDP or TWST?

Summary

How does Twist Bioscience compare to Revvity?

Do institutionals and insiders believe in TWST or RVTY?

Which has preferable earnings & valuation, TWST or RVTY?

Do analysts prefer TWST or RVTY?

Which has more volatility and risk, TWST or RVTY?

Does the media refer more to TWST or RVTY?

Is TWST or RVTY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools